학술논문

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Document Type
Article
Author
Eron, J.J.Cunningham, D.Orkin, C.Johnson, M.A.Cunningham, D.DeJesus, E.Pulido, F.Sogorb, J.P.Post, F.A.De Wit, S.Lathouwers, E.Hufkens, V.Petrovic, R.Brown, K.Van Landuyt, E.Opsomer, M.Jezorwski, J.Florence, E.Moutschen, M.Van Wijngaerden, E.Vandekerckhove, L.Vandercam, B.Brunetta, J.Conway, B.Klein, M.Murphy, D.Rachlis, A.Shafran, S.Walmsley, S.Ajana, F.Cotte, L.Girardy, P.-M.Katlama, C.Molina, J.-M.Poizot-Martin, I.Raffi, F.Rey, D.Reynes, J.Teicher, E.Yazdanpanah, Y.Gasiorowski, J.Halota, W.Horban, A.Piekarska, A.Witor, A.Arribas, J.R.Perez-Valero, I.Berenguer, J.Casado, J.Gatell, J.M.Gutierrez, F.Galindo, M.J.Gutierrez, M.D.M.Iribarren, J.A.Knobel, H.Negredo, E.Pineda, J.A.Podzamczer, D.Ricart, C.Rivero, A.Santos Gil, I.Blaxhult, A.Flamholc, L.Gisslèn, M.Thalme, A.Fehr, J.Rauch, A.Stoeckle, M.Clarke, A.Gazzard, B.G.Orkin, C.Post, F.Ustianowski, A.Waters, L.Bailey, J.Benson, P.Bhatti, L.Brar, I.Bredeek, U.F.Brinson, C.Crofoot, G.Dietz, C.Dretler, R.Felizarta, F.Fichtenbaum, C.Gallant, J.Gathe, J.Hagins, D.Henn, S.Henry, W.K.Huhn, G.Jain, M.Lucasti, C.Martorell, C.McDonald, C.Mills, A.Morales-Ramirez, J.Mounzer, K.Nahass, R.Olivet, H.Osiyemi, O.Prelutsky, D.Ramgopal, M.Rashbaum, B.Richmond, G.Ruane, P.Scarsella, A.Scribner, A.Shalit, P.Shamblaw, D.Slim, J.Tashima, K.Voskuhl, G.Ward, D.Wilkin, A.de Vente, J.
Source
In: Antiviral Research. (Antiviral Research, 01 October 2019, 170)
Subject
Language
English
ISSN
18729096
01663542